Alternative splicing of HER2: a novel mediator of EGFR TKI resistance

被引：1
|
作者：
Yochum, Zachary A. [1 ,2 ]
Villaruz, Liza C. [1 ]
机构：
[1] UPMC Hillman Canc Ctr, Dept Med, Div Hematol Oncol, Pittsburgh, PA USA
[2] Univ Pittsburgh, Sch Med, Med Scientist Training Program, Pittsburgh, PA USA
来源：
TRANSLATIONAL LUNG CANCER RESEARCH | 2020年 / 9卷 / 04期
关键词：
CELL LUNG-CANCER; PHASE-III; BREAST-CANCER; OPEN-LABEL; 1ST-LINE; AMPLIFICATION; OSIMERTINIB; MUTATION;
D O I：
10.21037/tlcr-20-618
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1606 / 1612
页数：7
相关论文
共 50 条
  • [1] Response to HER2 Inhibition in a Patient With Brain Metastasis With EGFR TKI Acquired Resistance and an HER2 Amplification
    Meedendorp, Arenda D.
    ter Elst, Arja
    't Hart, Nils A.
    Groen, Harry J. M.
    Schuuring, Ed
    van der Wekken, Anthonie J.
    FRONTIERS IN ONCOLOGY, 2018, 8
  • [2] Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors
    Kosaka, Takayuki
    Tanizaki, Junko
    Paranal, Raymond M.
    Endoh, Hideki
    Lydon, Christine
    Capelletti, Marzia
    Repellin, Claire E.
    Choi, Jihyun
    Ogino, Atsuko
    Calles, Antonio
    Ercan, Dalia
    Redig, Amanda J.
    Bahcall, Magda
    Oxnard, Geoffrey R.
    Eck, Michael J.
    Janne, Pasi A.
    CANCER RESEARCH, 2017, 77 (10) : 2712 - 2721
  • [3] Trastuzumab and paclitaxel in patients with EGFR mutated NSCLC that express HER2 after progression on EGFR TKI treatment
    de Langen, Adrianus J.
    Jebbink, M.
    Hashemi, Sayed M. S.
    Kuiper, Justine L.
    de Bruin-Visser, J.
    Monkhorst, Kim
    Thunnissen, Erik
    Smit, Egbert F.
    BRITISH JOURNAL OF CANCER, 2018, 119 (05) : 558 - 564
  • [4] Novel agents that downregulate EGFR, HER2, and HER3 in parallel
    Ferreira, Renan Barroso
    Law, Mary Elizabeth
    Jahn, Stephan Christopher
    Davis, Bradley John
    Heldermon, Coy Don
    Reinhard, Mary
    Castellano, Ronald Keith
    Law, Brian Keith
    ONCOTARGET, 2015, 6 (12) : 10445 - 10459
  • [5] HER2 equivocal breast cancer that is positive by alternative probe HER2 FISH are classified as HER2 negative by Oncotype DX
    Tozbikian, Gary H.
    Zynger, Debra L.
    BREAST JOURNAL, 2018, 24 (04) : 535 - 540
  • [6] Novel sulphonamide benzoquinazolinones as dual EGFR/HER2 inhibitors, apoptosis inducers and radiosensitizers
    Soliman, Aiten M.
    Alqahtani, Ali S.
    Ghorab, Mostafa
    JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 2019, 34 (01) : 1030 - 1040
  • [7] HER2 Amplification in Advanced NSCLC Patients After Progression on EGFR-TKI and Clinical Response to EGFR-TKI Plus Pyrotinib Combination Therapy
    Gan, Jiadi
    Huang, Yihua
    Liao, Jun
    Pang, Lanlan
    Fang, Wenfeng
    ONCOTARGETS AND THERAPY, 2021, 14 : 5297 - 5307
  • [8] Upregulation of Bcl2 in NSCLC with acquired resistance to EGFR-TKI
    Cheong, Hio Teng
    Xu, Fei
    Choy, Chi Tung
    Hui, Connie Wun Chun
    Mok, Tony Shu Kam
    Wong, Chi Hang
    ONCOLOGY LETTERS, 2018, 15 (01) : 901 - 907
  • [9] Impact of HER2 expression on EGFR-TKI treatment outcomes in lung tumors harboring EGFR mutations: A HER2-CS study subset analysis
    Ohashi, Kadoaki
    Ninomiya, Kiichiro
    Yoshioka, Hiroshige
    Bessho, Akihiro
    Shibayama, Takuo
    Aoe, Keisuke
    Ishikawa, Nobuhisa
    Kozuki, Toshiyuki
    Kawai, Haruyuki
    Kuyama, Shoichi
    Miyoshi, Seigo
    Fujitaka, Kazunori
    Obata, Hideto
    Tsubata, Yukari
    Awaya, Yoshikazu
    Inoue, Masaaki
    Inoue, Koji
    Horita, Naokatsu
    Yanai, Hiroyuki
    Hotta, Katsuyuki
    Kiura, Katsuyuki
    LUNG CANCER, 2020, 150 : 83 - 89
  • [10] Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer
    Yang, Lu
    Bhattacharya, Arup
    Li, Yun
    Sexton, Sandra
    Ling, Xiang
    Li, Fengzhi
    Zhang, Yuesheng
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2022, 41 (01)
12345